Cognition Therapeutics to detail Phase 3 plan for CT1812 in DLB psychosis
The July 16 fireside chat centers on a registrational Lewy body dementia psychosis study built on Phase 2 SHIMMER data, not new results from the ongoing Alzheimer's trial.
Executive Summary
- Cognition Therapeutics' CEO will use an investor conference appearance to update on the ongoing Alzheimer's disease trial and detail plans to start a registrational trial in a separate dementia indication.
- The company is shifting its most advanced late-stage ambitions toward dementia with Lewy bodies psychosis, built on a Phase 2 result in that population rather than on the Alzheimer's study still underway.
- The Alzheimer's trial that anchors the company's earlier-stage program has not reported a primary endpoint result, and its completion date has already moved once since the study began.
- The asset's mechanism has no other industry program at this stage in this population, leaving the company as the sole developer testing this approach to that specific target-indication pairing.
The appearance
Cognition Therapeutics, Inc. (Nasdaq: CGTX) said CEO Lisa Ricciardi will join a fireside discussion with analyst William Wood at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026, where she will review the status of the ongoing Phase 2 START study and outline the planned initiation of a Phase 3 registrational trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis. The company said the Phase 3 program follows efficacy signals from the completed Phase 2 SHIMMER study in DLB (NCT05225415), combined with the size of the market and unmet need in that population. CognitionCognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle ...Jul 13, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The Alzheimer's trial
The START study (NCT05531656) is testing zervimesine, an oral sigma-2 receptor antagonist, in 540 adults with MCI or mild Alzheimer's disease who are amyloid-biomarker positive, with the primary endpoint measuring change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), a standard cognitive-and-functional composite in early Alzheimer's trials. The trial moved to Active, not recruiting status in September 2025 after completing enrollment, and its primary completion date shifted from August 2026 to April 2027 in a single amendment made in September 2023. No results have posted on the registry to date. NCT05531656A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656
What the conference will and won't establish
The July 16 appearance is a status update and forward-looking discussion of trial plans, not a data disclosure: the company's own framing centers on reviewing where START stands operationally and describing the DLB psychosis program design, not reporting CDR-SB results from the Alzheimer's study. Zervimesine has been granted FDA Fast Track designation covering the company's Alzheimer's development program, including the SHINE study (NCT03507790) and START (NCT05531656). CognitionCognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle ...Jul 13, 2026
The competitive frame
Sigma-2 receptor antagonism has one active industry trial in Alzheimer's disease, the START study itself, alongside a single trial for the same target class in schizophrenia, Minerva Neurosciences' Phase 3 roluperidone program. Among small-molecule programs in Alzheimer's disease more broadly, competitors span a wide range of distinct mechanisms, including muscarinic agonists such as Bristol-Myers Squibb's KarXT and xanomeline programs, and PPAR-delta agonist T3D-959, none of which share CT1812's sigma-2 target. No sigma-2-targeted trial in Alzheimer's disease has been terminated to date.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.